Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Gilead Sciences, Inc.Trade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Gilead Sciences, Inc. trades at $136.19 (market cap $168.35B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Gilead Sciences, Inc. is far larger — about 2143.2× Inovio Pharmaceuticals Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

GILDINO
Market Cap
$168.35B$78.55M
Sector
HealthHealth
52-Week High
$155.80$2.87
52-Week Low
$110.56$0.66
Enterprise Value
$191.42B$49.56M
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO